- Hypothermic Perfusion Preservation (HPP)
- Static Cold Storage (SCS)
- Others
Lung Preservation Systems Market size was valued at USD 182.6 million in 2022 and is poised to grow at a CAGR of 6.8% from 2023 to 2029. Lung preservation is the process of protecting and maintaining the donor lung from lung procurement up to the implantation in the desired recipients. Perfusion volume and pressure, temperature, oxygenation, and degree of inflation are the key factors impact the lung injury during the preservation or at the time of preservation, and lung function after the transplantation to recipients. Lung procurement is usually performed after the brain death or cardiac death of the patients.
Global Lung Preservation Systems Market Summary
Study Period
2024-2030Base Year
2023CAGR
6.8%Largest Market
North AmericaFastest Growing Market
EuropeLung Preservation Systems Market Dynamics
Increase in the number of brain death cases due to rise in number of accidents and traumatic injuries is a key factor drives the global market. Moreover, increase in the awareness about the organ donation among the people, government initiations for the organ transplantation procedures, sophisticated healthcare infrastructure in the developed countries, rise in R&D expenditure for the development of newer methods for lungs storage, and favorable reimbursement policies are anticipated to spur the global market over the forecast period. However, high cost of procedure, dearth of skilled persons in underdeveloped regions, and limited scope at the end user level are hinder the growth of global lung preservation systems market.
North-America Got Significant Share
Lung Preservation Systems Market
Geographically, global lung preservation systems market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America market is poised to grow due to rise in lung transplantation procedures in U.S. and Canada, rise in consumption of tobacco and alcohol results to lung failure, and well developed healthcare infrastructure are propel the market. Europe market has prominent share attributed to increase in the recipients for lung transplantation for instance, according to European Commission 2014, approximately 2,100 lung recipients are in the waiting list, rise in healthcare expenditure, and presence of skilled professionals are boost the market. However, Asia Pacific market is driving by rise in medical tourism in Asia Pacific countries for organ transplantation, rise in awareness about the organ donation among the people, and entry of market players into Asia Pacific region are bolster the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Global Lung Preservation Systems Market Segmentation
By Technique
By Solution
- Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution
- Human Biosystem (HBS) Solution
- Renograf
- Viaspen
- Lifor
- Perfadex
- Others
By End User
- Hospitals
- Clinics
- Others
By Geography
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
Frequently Asked Questions
The key segments covered in the Lung Preservation Systems Market are technology, components, application, and end-users.
The Lung Preservation Systems Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Lung Preservation Systems Market key players are Franz Kohler Chemie GmbH (Germany), Organ Recovery Systems (U.S.), Waters Medical Systems LLC (U.S.), Essential Pharmaceuticals LLC (U.S.), Xvivo Perfusion AB (Sweden), BioLife Solutions, Inc. (U.S.), Preservation Solutions, Inc. (U.S.), Transmedics, Inc. (U.S.), CryoLife, Inc. (U.S.)
Key Features of the Report
- In April 2018, transmedics received FDA approval to launch its Organ Care System (OCS) Lung for use in standard double lung transplant procedures
| 1.Executive Summary |
| 2.Global Lung Preservation Systems Market Introduction |
| 2.1.Global Lung Preservation Systems Market - Taxonomy |
| 2.2.Global Lung Preservation Systems Market - Definitions |
| 2.2.1.Technique |
| 2.2.2.Solution |
| 2.2.3. End User |
| 2.2.4.Region |
| 3.Global Lung Preservation Systems Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Lung Preservation Systems Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Lung Preservation Systems Market By Technique, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Hypothermic Perfusion Preservation (HPP) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Static Cold Storage (SCS) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Lung Preservation Systems Market By Solution, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Human Biosystem (HBS) Solution |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Renograf |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Viaspen |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Lifor |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Perfadex |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7.Global Lung Preservation Systems Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Lung Preservation Systems Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Lung Preservation Systems Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Technique Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Hypothermic Perfusion Preservation (HPP) |
| 9.1.2.Static Cold Storage (SCS) |
| 9.1.3.Others |
| 9.2. Solution Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 9.2.2.Human Biosystem (HBS) Solution |
| 9.2.3.Renograf |
| 9.2.4.Viaspen |
| 9.2.5.Lifor |
| 9.2.6.Perfadex |
| 9.2.7.Others |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.3.3.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Lung Preservation Systems Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Hypothermic Perfusion Preservation (HPP) |
| 10.1.2.Static Cold Storage (SCS) |
| 10.1.3.Others |
| 10.2. Solution Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 10.2.2.Human Biosystem (HBS) Solution |
| 10.2.3.Renograf |
| 10.2.4.Viaspen |
| 10.2.5.Lifor |
| 10.2.6.Perfadex |
| 10.2.7.Others |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.3.3.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Lung Preservation Systems Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Hypothermic Perfusion Preservation (HPP) |
| 11.1.2.Static Cold Storage (SCS) |
| 11.1.3.Others |
| 11.2. Solution Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 11.2.2.Human Biosystem (HBS) Solution |
| 11.2.3.Renograf |
| 11.2.4.Viaspen |
| 11.2.5.Lifor |
| 11.2.6.Perfadex |
| 11.2.7.Others |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.3.3.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Lung Preservation Systems Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Hypothermic Perfusion Preservation (HPP) |
| 12.1.2.Static Cold Storage (SCS) |
| 12.1.3.Others |
| 12.2. Solution Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 12.2.2.Human Biosystem (HBS) Solution |
| 12.2.3.Renograf |
| 12.2.4.Viaspen |
| 12.2.5.Lifor |
| 12.2.6.Perfadex |
| 12.2.7.Others |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.3.3.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Lung Preservation Systems Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Technique Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Hypothermic Perfusion Preservation (HPP) |
| 13.1.2.Static Cold Storage (SCS) |
| 13.1.3.Others |
| 13.2. Solution Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Custodiol HTK - (Histidine-Tryptophan-Ketoglutarate) Solution |
| 13.2.2.Human Biosystem (HBS) Solution |
| 13.2.3.Renograf |
| 13.2.4.Viaspen |
| 13.2.5.Lifor |
| 13.2.6.Perfadex |
| 13.2.7.Others |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.3.3.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Franz Kohler Chemie GmbH (Germany) |
| 14.2.2.Organ Recovery Systems (U.S.) |
| 14.2.3.Waters Medical Systems LLC (U.S.) |
| 14.2.4.Essential Pharmaceuticals LLC (U.S.) |
| 14.2.5.Xvivo Perfusion AB (Sweden) |
| 14.2.6.BioLife Solutions, Inc. (U.S.) |
| 14.2.7.Preservation Solutions, Inc. (U.S.) |
| 14.2.8.Transmedics, Inc. (U.S.) |
| 14.2.9.CryoLife, Inc. (U.S.) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Franz Kohler Chemie GmbH (Germany)
- Organ Recovery Systems (U.S.)
- Waters Medical Systems LLC (U.S.)
- Essential Pharmaceuticals LLC (U.S.)
- Xvivo Perfusion AB (Sweden)
- BioLife Solutions, Inc. (U.S.)
- Preservation Solutions, Inc. (U.S.)
- Transmedics, Inc. (U.S.)
- CryoLife, Inc. (U.S.)